|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Sandy_Macrae
|
|
gptkbp:collaboratedWith
|
gptkb:Pfizer
gptkb:Takeda
gptkb:Biogen
gptkb:Sanofi
|
|
gptkbp:develops_treatment_for
|
gptkb:Fabry_disease
gptkb:beta-thalassemia
hemophilia
sickle cell disease
|
|
gptkbp:focusesOn
|
genetic disorder
genome editing
gene therapy
|
|
gptkbp:founded
|
1995
|
|
gptkbp:founder
|
gptkb:Edward_O._Lanphier_II
|
|
gptkbp:hasCompany
|
true
|
|
gptkbp:headquarters_location
|
gptkb:Brisbane,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sangamo Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:notableProduct
|
gptkb:ST-400_(gene-edited_cell_therapy_for_beta-thalassemia)
gptkb:ST-920_(gene_therapy_for_Fabry_disease)
SB-525 (gene therapy for hemophilia A)
BIVV003 (gene-edited cell therapy for sickle cell disease)
|
|
gptkbp:numberOfEmployees
|
approximately 300
|
|
gptkbp:platform
|
zinc finger nucleases
|
|
gptkbp:stockSymbol
|
gptkb:SGMO
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.sangamo.com/
|
|
gptkbp:bfsParent
|
gptkb:Takeda
gptkb:Sandy_Macrae
gptkb:Sangamo_Therapeutics_(collaboration)
|
|
gptkbp:bfsLayer
|
6
|